K
Kojin Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2020
Developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology MoreLess
Kojin Therapeutics is a cutting-edge biotech startup focused on developing innovative treatments for various diseases by targeting cellular states. The company operates in the life sciences and healthcare market, specifically within the realm of therapeutic development. Kojin's primary clients include pharmaceutical companies, research institutions, and healthcare providers who are seeking advanced solutions for complex medical conditions.
Kojin Therapeutics leverages groundbreaking scientific discoveries to create new medicines. The company’s approach involves understanding and manipulating the states of cells to treat diseases more effectively. This involves a deep dive into the cellular mechanisms and pathways that contribute to disease progression, and then developing drugs that can alter these pathways to achieve therapeutic benefits.
The business model of Kojin Therapeutics is centered around research and development (R&D). They invest heavily in scientific research to discover new drug candidates. Once a potential drug is identified, Kojin moves it through the stages of clinical development, which includes rigorous testing to ensure safety and efficacy. The company makes money through a combination of funding from venture capital firms, partnerships with larger pharmaceutical companies, and eventually, the sale or licensing of their developed drugs.
Kojin Therapeutics operates in a highly specialized and competitive market. However, their focus on cellular state manipulation sets them apart from many other biotech firms. By prioritizing the efficient translation of basic science into impactful medicines, they aim to bring transformative treatments to market more quickly and effectively.
In summary, Kojin Therapeutics is a biotech startup dedicated to developing new treatments by targeting cellular states, serving pharmaceutical companies and healthcare providers, and operating within the life sciences market. Their business model is based on R&D, and they generate revenue through venture funding, partnerships, and drug sales or licensing.
Keywords: biotech, therapeutics, cellular states, drug development, life sciences, healthcare, R&D, venture capital, pharmaceutical partnerships, innovative treatments.
Company overview
Kojin Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 63.9
Valuation & funding
Kojin Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2021 | $30M | $121M | Binney Street Capital | — |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | Dana-Farber Cancer Institute · Broad Institute · Harvard University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 6 |
| 2025 | 8 |
| 2024 | 33 |
| 2023 | 21 |
| 2022 | 25 |
| 2021 | 16 |
Growth signals
Kojin Therapeutics website traffic
Latest recorded traffic for Kojin Therapeutics is 1.4K monthly website visits, up 677.8% over the last three months. Kojin Therapeutics's team declined 12.5% over the past year.
Comparisons
Kojin Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Kojin Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on Kojin Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Kojin Therapeutics has talent and traffic
team presence
In the news
Latest news about Kojin Therapeutics
Recent press, funding announcements, and product moves mentioning Kojin Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Kojin Therapeutics
An AI-synthesized read of the highest-engagement posts about Kojin Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kojin Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.